Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 06, 2025 07:35 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropeniaon track for mid-2025 Right-sizing commercial efforts to optimize XOLREMDI promotion and support U.S. WHIM...
February 03, 2025 16:05 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective...
January 24, 2025 07:36 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

Submission supported by positive results from global, Phase 3 4WHIM clinical trial; U.S. regulatory approval in WHIM syndrome granted in 2024 Decision on MAA expected in 1H 2026 BOSTON, Jan. ...
January 13, 2025 07:35 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the mid-twenties ...
December 04, 2024 08:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition

BOSTON, Dec. 04, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced its upcoming...
December 03, 2024 16:05 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective...
November 26, 2024 08:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference

BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management...
November 14, 2024 08:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management...
November 13, 2024 06:07 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced today Pivotal Phase 3 trial of mavorixafor in CN on track to fully enroll in mid-2025 U.S. launch...
November 13, 2024 06:01 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

Mavorixafor durably and meaningfully elevated participants’ mean absolute neutrophil counts (ANC) Mavorixafor enabled substantial reductions in G-CSF dosing while maintaining mean ANC at normal...